Literature DB >> 36042131

Contribution of hyperglycemia-induced changes in microglia to Alzheimer's disease pathology.

Maricarmen Hernández-Rodríguez1, Cecilia Flores Clemente2, Martha Edith Macías-Pérez3, Rolando Alberto Rodríguez-Fonseca3, M Inés Nicolás Vázquez4, Joel Martínez4,5, Rene Miranda Ruvalcaba4, Martín Martínez Rosas6, Elvia Mera Jiménez7.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative condition characterized by cognitive and functional impairments. The investigation of AD has focused on the formation of senile plaques, composed mainly by amyloid β (Aβ) peptide, and neurofibrillary tangles (NFTs) in the brain. Senile plaques and NFTs cause the excessive recruitment and activation of microglia, thus generating neuroinflammation and neuronal damage. Among the risk factors for the development of AD, diabetes has increasingly attracted attention. Hyperglycemia, the fundamental characteristic of diabetes, is involved in several mechanisms that give rise to microglial overactivation, resulting in neuronal damage and cognitive impairment. Indeed, various studies have identified the correlation between diabetes and AD. The aim of this review is to describe various mechanisms of the hyperglycemia-induced overactivation of microglia, which leads to neuroinflammation and neuronal damage and consequently contributes to the pathology of AD. The disruption of the regulation of microglial activity by hyperglycemia occurs through many mechanisms, including a greater production of reactive oxygen species (ROS) and glycation end products (AGEs), and a decrease in the elimination of Aβ. The future direction of research on the relation between hyperglycemia and AD is addressed, such as the importance of determining whether the hyperglycemia-induced harmful effects on microglial activity can be reversed or attenuated if blood glucose returns to a normal level.
© 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid beta; Diabetes; Hyperglycemia; Microglia; Tau protein

Mesh:

Substances:

Year:  2022        PMID: 36042131     DOI: 10.1007/s43440-022-00405-9

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.919


  144 in total

Review 1.  The vexing complexity of the amyloidogenic pathway.

Authors:  Manuel A Castro; Arina Hadziselimovic; Charles R Sanders
Journal:  Protein Sci       Date:  2019-04-11       Impact factor: 6.725

Review 2.  Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications.

Authors:  Geert Jan Biessels; Florin Despa
Journal:  Nat Rev Endocrinol       Date:  2018-10       Impact factor: 43.330

Review 3.  Time to test antibacterial therapy in Alzheimer's disease.

Authors:  Francesco Panza; Madia Lozupone; Vincenzo Solfrizzi; Mark Watling; Bruno P Imbimbo
Journal:  Brain       Date:  2019-10-01       Impact factor: 13.501

Review 4.  Towards an understanding of amyloid-β oligomers: characterization, toxicity mechanisms, and inhibitors.

Authors:  Shin Jung C Lee; Eunju Nam; Hyuck Jin Lee; Masha G Savelieff; Mi Hee Lim
Journal:  Chem Soc Rev       Date:  2017-01-23       Impact factor: 54.564

Review 5.  Diabetes and cognitive dysfunction.

Authors:  Rory J McCrimmon; Christopher M Ryan; Brian M Frier
Journal:  Lancet       Date:  2012-06-09       Impact factor: 79.321

Review 6.  Amyloid precursor protein processing and Alzheimer's disease.

Authors:  Richard J O'Brien; Philip C Wong
Journal:  Annu Rev Neurosci       Date:  2011       Impact factor: 12.449

Review 7.  Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer's disease.

Authors:  Darshpreet Kaur; Vivek Sharma; Rahul Deshmukh
Journal:  Inflammopharmacology       Date:  2019-03-14       Impact factor: 4.473

Review 8.  Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage.

Authors:  P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2013-06-28

9.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans.

Authors:  D W Dickson; H A Crystal; L A Mattiace; D M Masur; A D Blau; P Davies; S H Yen; M K Aronson
Journal:  Neurobiol Aging       Date:  1992 Jan-Feb       Impact factor: 4.673

10.  Cellular and Molecular Mediators of Neuroinflammation in Alzheimer Disease.

Authors:  Seung-Hoon Yang
Journal:  Int Neurourol J       Date:  2019-11-30       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.